Outlook Therapeutics, Inc. Reports Q4 and FY2025 Financial Results

Outlook Therapeutics, Inc. announced its financial results for the fourth fiscal quarter and the full fiscal year ended September 30, 2025. The company reported a net loss attributable to common stockholders of $62.4 million, or $1.79 per basic and diluted share, for fiscal year 2025, compared to a net loss of $75.4 million, or $4.06 per basic and diluted share, in the prior year. Revenue for fiscal year 2025 was $1.4 million, primarily from initial sales of LYTENAVA™ in Germany and the UK. Overall expenses decreased by $4.6 million due to reduced R&D expenses, though SG&A expenses increased related to the European launch of LYTENAVA™. As of September 30, 2025, the company had $8.1 million in cash and cash equivalents. The company is awaiting a decision from the FDA on ONS-5010, with a PDUFA goal date of December 31, 2025. Commercial activities are ongoing in Europe, with plans for further market expansion.